Treatment News : PrEP Did Not Increase Sexual Risks in Study of Gay Men

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 6, 2013

PrEP Did Not Increase Sexual Risks in Study of Gay Men

Pre-exposure prophylaxis (PrEP) did not cause men who have sex with men (MSM) to have riskier sex in a recent trial. However, the study has various important limitations and does not necessarily reflect a real-world setting. Publishing their findings in the Journal of Acquired Immune Deficiency Syndromes, researchers conducted a randomized, double-blind, placebo-controlled trial of Viread (tenofovir) as PrEP with 400 HIV-negative MSM in San Francisco, Atlanta and Boston who had reported anal sex with another man during the past year.

PrEP, in which an HIV antiretroviral or combination ARV pill is taken daily by HIV-negative people at high risk for infection, has been shown in recent research with MSM to significantly lower the risk of transmission. A major concern among researchers, however, is that PrEP will lead to a phenomenon known as risk compensation: If people taking the therapy consider themselves more invincible to infection, they might take more sexual risks.

The study participants were randomly and evenly divided into four groups, receiving either Viread or a placebo, and starting therapy either upon entering the study, or after a delay of nine months, and then continuing for 24 months. The researchers assessed the participants’ sexual risk factors at the beginning of the study, and then the participants returned every three months to give follow-up interviews.

During the follow-up period, the men’s risk factors either dropped or stayed level, with the average number of sexual partners and the percentage reporting unprotected anal intercourse (UAI) falling and the average number of instances of UAI not changing significantly. During the beginning nine-month period when one half of the group was delayed in taking either Viread or the placebo, changes in risk practices were similar between the two groups. These figures did not change significantly once both groups were taking the therapy or placebo.

The study has some very important limitations: The participants were told that PrEP had no known efficacy, so their willingness to take risks might not translate to real-world scenarios in which men know the therapy could protect them against HIV. The participants’ knowledge that they may have been taking a placebo may also have made them more cautious. Furthermore, self-reports of sexual risk taking may be unreliable, and the men may have been inclined to give more favorable replies, depicting their behavior as less risky than it actually was.

To read the study abstract, click here.

Search: PrEP, pre-exposure prophylaxis, HIV, gay men, men who have sex with men, MSM, Journal of Acquired Immune Deficiency Syndromes, Viread, tenofovir, risk compensation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.